



## Press Release

### TxCell: Full-year report on liquidity contract with Oddo Corporate Finance

**Valbonne, France, January 4, 2016** – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, today reports the full-year report of its liquidity contract with Oddo Corporate Finance.

Under the liquidity contract entrusted to Oddo Corporate Finance, for the shares of the company TxCell, as at December 31, 2015, the following assets appeared on the liquidity account:

- Number of shares: 16,280 shares
- Cash balance on the liquidity account: 104,628.82 euros

As a reminder, at June 30, 2015, the following assets appeared on the liquidity account:

- Number of shares: 11,076 shares
- Cash balance on the liquidity account: 124,877.20 euros

Also as a reminder, the following assets appeared on the liquidity account at its start:

- Number of shares: 0 share
- Cash balance on the liquidity account: 200,000.00 euros

**About TxCell:** [www.txcell.com](http://www.txcell.com)

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell's lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 60 employees.

#### Contacts:

##### **TxCell**

Raphaël Flipo  
CFO  
Tél: +33 4 97 21 83 00  
[contact@txcell.com](mailto:contact@txcell.com)

##### **NewCap**

Financial Communication  
Julien Perez / Pierre Laurent  
Tél: +33 1 44 71 94 94  
[txcell@newcap.eu](mailto:txcell@newcap.eu)



**Disclaimer:**

This press release contains certain forward-looking statements concerning TxCell and its business. Such forward-looking statements are based on assumptions that TxCell considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of TxCell registered by the French Financial Markets Authority (*Autorité des marchés financiers*) on June 11, 2015 under number R. 15-049 and in the half year financial report of TxCell as of June 30, 2015 (a copy of which is available on [www.txcell.com](http://www.txcell.com)) and to the development of economic conditions, financial markets and the markets in which TxCell operates. The forward-looking statements contained in this press release are also subject to risks not yet known to TxCell or not currently considered material by TxCell. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of TxCell to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, TxCell shares in any country.